Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CR Pharma Negotiating for China Rights to Two Xbrane Candidates

publication date: Jan 16, 2018

CR Pharma, China's second-largest drugmaker, is negotiating with Sweden's Xbrane Biopharma for China rights to two Xbrane candidates. One of the drugs is Spherotide, a generic testosterone suppressor with an extended release delivery used to treat prostate cancer. The other is Xlucane, a biosimilar to Roche's Lucentis, a treatment for wet age-related macular degeneration. According to Xbrane, it has held final negotiations for China rights to Spherotide, though an agreement has not been signed. So far, it has agreed only to a non-binding letter of intent for Xlucane, with terms still to be discussed. More details....

Stock Symbol: (HK: 3320)

Share this with colleagues:

>



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital